NCT06829459View on ClinicalTrials.gov

A Study to Evaluate the Efficacy and Safety of Glumetinib Combined With Osimertinib Mesylate Versus Platinum-based Doublet Chemotherapy in Non-Small Cell Lung Cancer Patients After Resistance to EGFR-TKIs

PHASE3RecruitingINTERVENTIONAL
Enrollment

350

Participants

Timeline

Start Date

April 3, 2025

Primary Completion Date

February 15, 2028

Study Completion Date

February 15, 2029

Conditions
Non-Small Cell Lung Cancer
Interventions
DRUG

Glumetinib

Patients will be administered glumetinib 300 mg/dose once daily once daily under fasting conditions in each 21-day treatment cycle.

DRUG

Osimertinib mesylate

Patients will be administered osimertinib mesylate 80 mg/dose once daily under fasting conditions in each 21-day treatment cycle.

DRUG

Pemetrexed

Patients will be administered pemetrexed 500 mg/m\^2 via intravenous infusion on the first day of each 3-week cycle.

DRUG

Cisplatin or carboplatin

Patients will be administered cisplatin 75 mg/m\^2 or carboplatin AUC=5 via intravenous infusion on the first day of each 3-week cycle

Trial Locations (1)

100021

RECRUITING

Cancer Hospital Chinese Academy of Medical Sciences, Beijing

All Listed Sponsors
lead

Shanghai JMT-Bio Inc.

INDUSTRY